These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 35660482)

  • 21. [Craniopharyngiomas: The Dawn of a New Era with the Elucidation of Driver Genes].
    Fujio S; Hanaya R
    No Shinkei Geka; 2023 Sep; 51(5):917-928. PubMed ID: 37743344
    [TBL] [Abstract][Full Text] [Related]  

  • 22. ENDOCRINE TUMORS: BRAF V600E mutations in papillary craniopharyngioma.
    Brastianos PK; Santagata S
    Eur J Endocrinol; 2016 Apr; 174(4):R139-44. PubMed ID: 26563980
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Iconographic analysis for pituitary adenoma, craniopharyngioma and Rathke cleft cyst involving both intrasellar and suprasellar regions].
    Song CQ; Ren XH; Sui DL; Lin S; Zhang Y
    Zhonghua Yi Xue Za Zhi; 2013 Dec; 93(45):3610-3. PubMed ID: 24534313
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differential expression of cytokeratins 8 and 20 distinguishes craniopharyngioma from rathke cleft cyst.
    Xin W; Rubin MA; McKeever PE
    Arch Pathol Lab Med; 2002 Oct; 126(10):1174-8. PubMed ID: 12296753
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of CTNNB1 Mutation Status in Pediatric Cystic Adamantinomatous Craniopharyngioma by Using Preoperative Magnetic Resonance Imaging Manifestation.
    Zhu W; Tang T; Yuan S; Chang B; Li S; Chen M
    Clin Neurol Neurosurg; 2021 Jan; 200():106347. PubMed ID: 33160718
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Case report and literature review of BRAF-V600 inhibitors for treatment of papillary craniopharyngiomas: A potential treatment paradigm shift.
    Nussbaum PE; Nussbaum LA; Torok CM; Patel PD; Yesavage TA; Nussbaum ES
    J Clin Pharm Ther; 2022 Jun; 47(6):826-831. PubMed ID: 35023192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Study of β-catenin and BRAF alterations in adamantinomatous and papillary craniopharyngiomas: mutation analysis with immunohistochemical correlation in 54 cases.
    Malgulwar PB; Nambirajan A; Pathak P; Faruq M; Suri V; Sarkar C; Jagdevan A; Sharma BS; Sharma MC
    J Neurooncol; 2017 Jul; 133(3):487-495. PubMed ID: 28500561
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Collision sellar lesions: coexistence of pituitary adenoma and Rathke cleft cyst-a single-center experience.
    de Almeida Verdolin A; Lamback EB; Ventura N; Guasti A; da Mata Pereira PJ; Gadelha MR; Chimelli L
    Endocrine; 2020 Apr; 68(1):174-181. PubMed ID: 31802354
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dramatic Response of BRAF V600E Mutant Papillary Craniopharyngioma to Targeted Therapy.
    Brastianos PK; Shankar GM; Gill CM; Taylor-Weiner A; Nayyar N; Panka DJ; Sullivan RJ; Frederick DT; Abedalthagafi M; Jones PS; Dunn IF; Nahed BV; Romero JM; Louis DN; Getz G; Cahill DP; Santagata S; Curry WT; Barker FG
    J Natl Cancer Inst; 2016 Feb; 108(2):. PubMed ID: 26498373
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Neoadjuvant B-RAF and MEK Inhibitor Targeted Therapy for Adult Papillary Craniopharyngiomas: A New Treatment Paradigm.
    Calvanese F; Jacquesson T; Manet R; Vasiljevic A; Lasolle H; Ducray F; Raverot G; Jouanneau E
    Front Endocrinol (Lausanne); 2022; 13():882381. PubMed ID: 35757402
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pituitary adenoma, craniopharyngioma, and Rathke cleft cyst involving both intrasellar and suprasellar regions: differentiation using MRI.
    Choi SH; Kwon BJ; Na DG; Kim JH; Han MH; Chang KH
    Clin Radiol; 2007 May; 62(5):453-62. PubMed ID: 17398271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Therapeutic outcomes of transsphenoidal surgery in pediatric patients with craniopharyngiomas: a single-center study.
    Yamada S; Fukuhara N; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Inoshita N; Ito J
    J Neurosurg Pediatr; 2018 Jun; 21(6):549-562. PubMed ID: 29600905
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Presentation and outcomes in surgically and conservatively managed pediatric Rathke cleft cysts.
    Shepard MJ; Elzoghby MA; Kiehna EN; Payne SC; Jane JA
    J Neurosurg Pediatr; 2018 Mar; 21(3):308-314. PubMed ID: 29271731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. BRAF V600E mutations are characteristic for papillary craniopharyngioma and may coexist with CTNNB1-mutated adamantinomatous craniopharyngioma.
    Larkin SJ; Preda V; Karavitaki N; Grossman A; Ansorge O
    Acta Neuropathol; 2014; 127(6):927-9. PubMed ID: 24715106
    [No Abstract]   [Full Text] [Related]  

  • 35. BRAF V600E mutant papillary craniopharyngiomas: a single-institutional case series.
    La Corte E; Younus I; Pivari F; Selimi A; Ottenhausen M; Forbes JA; Pisapia DJ; Dobri GA; Anand VK; Schwartz TH
    Pituitary; 2018 Dec; 21(6):571-583. PubMed ID: 30187175
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pathological and Prognostic Characterization of Craniopharyngioma Based on the Expression of TrkA, β-Catenin, Cell Cycle Markers, and BRAF V600E Mutation.
    Xu C; Ge S; Cheng J; Gao H; Zhang F; Han A
    Front Endocrinol (Lausanne); 2022; 13():859381. PubMed ID: 35707464
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiological features of craniopharyngiomas located in the posterior fossa.
    Zhou L; Li Q; Luo L; Xu J; Zhang Y; Chen T; Wei Y; You C
    J Neurol Sci; 2009 Dec; 287(1-2):119-25. PubMed ID: 19758604
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Successful Use of BRAF/MEK Inhibitors as a Neoadjuvant Approach in the Definitive Treatment of Papillary Craniopharyngioma.
    Khaddour K; Chicoine MR; Huang J; Dahiya S; Ansstas G
    J Natl Compr Canc Netw; 2020 Dec; 18(12):1590-1595. PubMed ID: 33285519
    [TBL] [Abstract][Full Text] [Related]  

  • 39. TREM-1 expression in craniopharyngioma and Rathke's cleft cyst: its possible implication for controversial pathology.
    Liu Y; Wang CH; Li DL; Zhang SC; Peng YP; Peng JX; Song Y; Qi ST; Pan J
    Oncotarget; 2016 Aug; 7(31):50564-50574. PubMed ID: 27409178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Approach to the Patient: Differential Diagnosis of Cystic Sellar Lesions.
    Gadelha MR; Wildemberg LE; Lamback EB; Barbosa MA; Kasuki L; Ventura N
    J Clin Endocrinol Metab; 2022 May; 107(6):1751-1758. PubMed ID: 35092687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.